|Mr. Alexis Rideau||Chief Exec. Officer||N/A||N/A||N/A|
|Prof. Miroslav Radman||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Mario Alcaraz||Chief Financial & Admin. Officer||N/A||N/A||N/A|
|Dr. Georges Gaudriault Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Johane Rinaldi||Chief HR Officer||N/A||N/A||N/A|
|Dr. Yannick Pletan||Chief Medical Officer & Independent Director||N/A||N/A||N/A|
DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME OlÃ©oactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioMÃ©rieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, OlÃ©os-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.
Deinove SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.